AAAAAA
Results: 1-25/44
Authors:
Doser, N
Sudre, P
Telenti, A
Wietlisbach, V
Nicod, P
Darioli, R
Mooser, V
Citation: N. Doser et al., Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen, J ACQ IMM D, 26(4), 2001, pp. 389-390
Authors:
Rossi, M
Flepp, M
Telenti, A
Schiffer, V
Egloff, N
Bucher, H
Vernazza, P
Bernasconi, E
Weber, R
Rickenbach, M
Furrer, H
Citation: M. Rossi et al., Disseminated M-avium complex infection in the Swiss HIV cohort study: Declining incidence, improved prognosis and discontinuation of maintenance therapy, SWISS MED W, 131(31-32), 2001, pp. 471-477
Authors:
Marzolini, C
Telenti, A
Decosterd, L
Biollaz, J
Buclin, T
Citation: C. Marzolini et al., 'Efavirenz plasma levels can predict treatment failure and central nervoussystem side effects in HIV-1-infected patients', AIDS, 15(9), 2001, pp. 1193-1194
Authors:
Bernasconi, E
Uhr, M
Magenta, L
Ranno, A
Telenti, A
Citation: E. Bernasconi et al., Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy, AIDS, 15(8), 2001, pp. 1081-1082
Authors:
Furrer, H
Opravil, M
Rossi, M
Bernasconi, E
Telenti, A
Bucher, H
Schiffer, V
Boggian, K
Rickenbach, M
Flepp, M
Egger, M
Citation: H. Furrer et al., Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study, AIDS, 15(4), 2001, pp. 501-507
Authors:
Depairon, M
Chessex, S
Sudre, P
Rodondi, N
Doser, N
Chave, JP
Riesen, W
Nicod, P
Darioli, R
Telenti, A
Mooser, V
Citation: M. Depairon et al., Premature atherosclerosis in HIV-infected individuals - focus on protease inhibitor therapy, AIDS, 15(3), 2001, pp. 329-334
Authors:
Marzolini, C
Chave, JP
Telenti, A
Brenas-Chinchon, L
Biollaz, J
Citation: C. Marzolini et al., Impaired absorption of rifabutin by concomitant administration of didanosine, AIDS, 15(16), 2001, pp. 2203-2204
Authors:
Friedl, AC
Ledergerber, B
Flepp, M
Hirschel, B
Telenti, A
Furrer, H
Bucher, HC
Bernasconi, E
Weber, R
Citation: Ac. Friedl et al., Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy - The Swiss HIV Cohort Study, AIDS, 15(14), 2001, pp. 1793-1800
Authors:
Marzolini, C
Telenti, A
Decosterd, LA
Greub, G
Biollaz, J
Buclin, T
Citation: C. Marzolini et al., Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients, AIDS, 15(1), 2001, pp. 71-75
Authors:
Marzolini, C
Buclin, T
Decosterd, LA
Biollaz, J
Telenti, A
Citation: C. Marzolini et al., Nelfinavir plasma levels under twice-daily and three-times-daily regimens:High interpatient and low intrapatient variability, THER DRUG M, 23(4), 2001, pp. 394-398
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Authors:
Fellay, J
Boubaker, K
Ledergerber, B
Bernasconi, E
Furrer, H
Battegay, M
Hirschel, B
Vernazza, P
Francioli, P
Greub, G
Flepp, M
Telenti, A
Citation: J. Fellay et al., Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study, LANCET, 358(9290), 2001, pp. 1322-1327
Authors:
Greub, G
Ledergerber, B
Telenti, A
Citation: G. Greub et al., HIV-1 progression in hepatitis-C-infected drug users - Reply, LANCET, 357(9265), 2001, pp. 1363-1363
Authors:
Guex-Crosier, Y
Telenti, A
Citation: Y. Guex-crosier et A. Telenti, An epidemic of blindness: a consequence of improved HIV care?, B WHO, 79(3), 2001, pp. 181-181
Authors:
Bleiber, G
Munoz, M
Ciuffi, A
Meylan, P
Telenti, A
Citation: G. Bleiber et al., Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1, J VIROLOGY, 75(7), 2001, pp. 3291-3300
Authors:
Peters, S
Munoz, M
Yerly, S
Sanchez-Merino, V
Lopez-Galindez, C
Perrin, L
Larder, B
Cmarko, D
Fakan, S
Meylan, P
Telenti, A
Citation: S. Peters et al., Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein, J VIROLOGY, 75(20), 2001, pp. 9644-9653
Authors:
Marzolini, C
Telenti, A
Buclin, T
Biollaz, J
Decosterd, LA
Citation: C. Marzolini et al., Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction, J CHROMAT B, 740(1), 2000, pp. 43-58
Authors:
Telenti, A
Rizzardi, GP
Citation: A. Telenti et Gp. Rizzardi, Limits to potent antiretroviral therapy, REV MED VIR, 10(6), 2000, pp. 385-393
Authors:
Meystre-Agustoni, G
Dubois-Arber, F
Cochand, P
Telenti, A
Citation: G. Meystre-agustoni et al., Antiretroviral therapies from the patient's perspective, AIDS CARE, 12(6), 2000, pp. 717-721
Authors:
Bally, F
Martinez, R
Peters, S
Sudre, P
Telenti, A
Citation: F. Bally et al., Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors, AIDS RES H, 16(13), 2000, pp. 1209-1213
Authors:
Marzolini, C
Troillet, N
Telenti, A
Baumann, P
Decosterd, LA
Eap, CB
Citation: C. Marzolini et al., Efavirenz decreases methadone blood concentrations, AIDS, 14(9), 2000, pp. 1291-1292
Authors:
Khanna, N
Klimkait, T
Schiffer, V
Irigoyen, J
Telenti, A
Hirschel, B
Battegay, M
Citation: N. Khanna et al., Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients (vol 14, pg 791, 2000), AIDS, 14(9), 2000, pp. 1297-1297
Authors:
Khanna, N
Klimkait, T
Schiffer, V
Irigoyen, J
Telenti, A
Hirschel, B
Battegay, M
Citation: N. Khanna et al., Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients, AIDS, 14(7), 2000, pp. 791-799
Authors:
Aebi, C
Battegay, M
Bernasconi, E
Biedermann, K
Cheseaux, JJ
Drack, G
Erb, P
Flepp, M
Francioli, P
Furrer, HJ
Gianinazzi, MP
Gyr, T
Hirschel, B
Hosli, I
Hug, I
Irion, O
Keller, K
Kind, C
Laubereau, B
Lauper, U
Lorenzi, P
Matter, L
Nadal, D
Perrin, L
Rickenbach, M
Rudin, C
Schreyer, A
Schupbach, J
Telenti, A
Vernazza, P
Wolf, K
Wunder, D
Wyler, CA
Giaquinto, C
Ruga, E
De Rossi, A
Grosch-Worner, I
Seel, K
Schafer, A
Mok, J
Johnstone, F
Jimenez, J
Garcia-Rodriguez, MC
Bates, I
de Jose, I
Hawkins, F
de Gevara, CL
Pena, JM
Garcia, JG
Lopez, JRA
Asensi-Botet, F
Otero, MC
Perez-Tamarit, D
Ridaura, S
Gregori, P
de la Torre, R
Scherpbier, H
Kreyenbroek, M
Boer, K
Bohlin, AB
Lindgren, S
Ehrnst, A
Belfrage, E
Lidman, K
Christensson, B
Levy, J
Hainaut, M
Peltier, A
Barlow, P
Wibaut, S
Lecroart, MC
Ferrazin, A
Bassetti, D
De Maria, A
Gotta, C
Mur, A
Paya, A
Vinolas, M
Lopez-Vilchez, MA
Martinez-Gomez, P
Carreras, R
Coll, O
Fortuny, C
Boguna, J
Caro, MC
Canet, Y
Pardi, G
Ravizza, M
Guerra, B
Lanari, M
Bianchi, S
Bovicelli, L
Prati, E
Duse, M
Scaravelli, G
Stegagno, M
De Santis, M
Semprini, AE
Savasi, V
Vigano, A
Probizer, FR
Maccabruni, A
Bucceri, A
Rancilio, L
Taylor, GP
Lyall, H
Penn, Z
Valerius, NH
Martinelli, P
Buffolano, W
Sansone, M
Tibaldi, C
Ziarati, N
Benedetto, C
Niemiec, T
Horban, A
Citation: C. Aebi et al., Combination antiretroviral therapy and duration of pregnancy, AIDS, 14(18), 2000, pp. 2913-2920
Authors:
Rutschmann, OT
Vernazza, PL
Bucher, HC
Opravil, M
Ledergerber, B
Telenti, A
Malinverni, R
Bernasconi, E
Fagard, C
Leduc, D
Perrin, L
Hirschel, B
Citation: Ot. Rutschmann et al., Long-term hydroxyurea in combination with didanosine and stavudine for thetreatment of HIV-1 infection, AIDS, 14(14), 2000, pp. 2145-2151
Authors:
Kaufmann, D
Munoz, M
Bleiber, G
Fleury, S
Lotti, B
Martinez, R
Pichler, W
Meylan, P
Telenti, A
Citation: D. Kaufmann et al., Virological and immunological characteristics of HIV treatment failure, AIDS, 14(12), 2000, pp. 1767-1774